NL-OMON26884招募中不适用
Vedolizumab in PSC and concurrent IBD:Searching for the missing link between the gut and the liver, and exploration of biomarkers for development of colorectal carcinoma
Academic Medical Center (AMC), Amsterdam0 个研究点目标入组 40 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •- Diagnosis of PSC, established by cholangiography, in whom secondary causes of sclerosing cholangitis have been excluded
排除标准
- •- Medical history of proctocolectomy
- •- Use of biologic therapy other than vedolizumab within 8 weeks of enrolment
研究者
相似试验
招募中
不适用
Vedolizumab in PSC and concurrent IBD: Searching for the missing link between the gut and the liver and exploration of biomarkers for development of colorectal carcinoma.NL-OMON55753Academisch Medisch Centrum40
已完成
不适用
Vedolizumab Study with Inflammatory Bowel Disease Patients in GermanyK50K51Crohn disease [regional enteritis]Ulcerative colitisDRKS00013251CED Service GmbH1,280
已完成
不适用
A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in Real-World PracticeInflammatory Bowel DiseasesCrohns DiseaseColitis, UlcerativeNCT04890262Takeda99
已完成
1 期
Using Vedolizumab-800CW to Gain Insight Into Local Drug Distribution and Mucosal Target Cells in IBD PatientsColitis, UlcerativeCrohn DiseaseNCT04112212University Medical Center Groningen38
招募中
4 期
Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.Crohn's DiseaseNCT06180382Centre Hospitalier Universitaire de Saint Etienne220